Everest Pharma Announces Launch of Ascimib, FDA-Approved Generic for Asciminib FDA grants accelerated approval to Asciminib for newly diagnosed Chronic Myeloid Leukemia Asciminib emerges as a promising option for frontline management of Ph+ CML in chronic phase (CP)
